Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Net Income (2022 - 2025)

Atara Biotherapeutics' Net Income history spans 4 years, with the latest figure at -$3.4 million for Q4 2025.

  • For Q4 2025, Net Income rose 72.94% year-over-year to -$3.4 million; the TTM value through Dec 2025 reached $32.7 million, up 138.32%, while the annual FY2025 figure was $32.7 million, 138.32% up from the prior year.
  • Net Income reached -$3.4 million in Q4 2025 per ATRA's latest filing, up from -$4.3 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $38.0 million in Q1 2025 to a low of -$88.1 million in Q1 2022.
  • Average Net Income over 4 years is -$34.8 million, with a median of -$26.8 million recorded in 2024.
  • Peak YoY movement for Net Income: tumbled 485.08% in 2023, then surged 219.71% in 2025.
  • A 4-year view of Net Income shows it stood at -$74.6 million in 2022, then increased by 18.6% to -$60.7 million in 2023, then soared by 79.26% to -$12.6 million in 2024, then skyrocketed by 72.94% to -$3.4 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Net Income are -$3.4 million (Q4 2025), -$4.3 million (Q3 2025), and $2.4 million (Q2 2025).